Karyopharm Therapeutics (KPTI) News Today $3.86 -0.20 (-4.93%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$3.82 -0.04 (-1.04%) As of 04/3/2025 04:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average - Here's WhyApril 2 at 2:57 AM | americanbankingnews.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1 at 4:05 PM | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Crosses Below 200-Day Moving Average - Here's What HappenedKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below 200-Day Moving Average - Here's WhyMarch 25, 2025 | marketbeat.comKaryopharm price target lowered to split-adjusted $15 from $75 at Piper SandlerMarch 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics (KPTI) Receives a Buy from Piper SandlerMarch 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 23.7% in FebruaryKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,060,000 shares, a decline of 23.7% from the February 13th total of 1,390,000 shares. Based on an average trading volume of 92,200 shares, the days-to-cover ratio is currently 11.5 days. Approximately 13.5% of the company's stock are short sold.March 18, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average - Time to Sell?Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average - Here's What HappenedMarch 11, 2025 | marketbeat.comXPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APACMarch 5, 2025 | prnewswire.comKaryopharm price target lowered to $54 from $75 at BairdMarch 3, 2025 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Given New $54.00 Price Target at Robert W. BairdRobert W. Baird lowered their price target on Karyopharm Therapeutics from $75.00 to $54.00 and set an "outperform" rating on the stock in a report on Monday.March 3, 2025 | marketbeat.comQ1 EPS Estimate for Karyopharm Therapeutics Cut by AnalystKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share estimates for shares of Karyopharm Therapeutics in a report issued on Wednesday, February 26th. HC Wainwright analyst E. White now forecasts that the comMarch 3, 2025 | marketbeat.comKaryopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal yearFebruary 28, 2025 | uk.investing.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Short Interest Down 93.1% in FebruaryKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) saw a large drop in short interest during the month of February. As of February 15th, there was short interest totalling 1,390,000 shares, a drop of 93.1% from the January 31st total of 20,140,000 shares. Based on an average daily trading volume, of 72,300 shares, the days-to-cover ratio is presently 19.2 days. Approximately 17.9% of the shares of the company are sold short.February 28, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9% - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Down 9% - Should You Sell?February 28, 2025 | marketbeat.comKaryopharm Therapeutics (KPTI) to Release Quarterly Earnings on ThursdayKaryopharm Therapeutics (NASDAQ:KPTI) will be releasing earnings before the market opens on Thursday, March 6. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665471)February 27, 2025 | marketbeat.comKaryopharm trading halted, news pendingFebruary 26, 2025 | markets.businessinsider.comKaryopharm target adjusted to $7 from $56 at H.C. WainwrightFebruary 26, 2025 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Sees Strong Trading Volume Following Analyst UpgradeKaryopharm Therapeutics (NASDAQ:KPTI) Sees Unusually-High Trading Volume Following Analyst UpgradeFebruary 26, 2025 | marketbeat.comHC Wainwright Issues Positive Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock PriceHC Wainwright increased their price objective on shares of Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a "buy" rating in a research note on Wednesday.February 26, 2025 | marketbeat.comKaryopharm Therapeutics Inc.: Karyopharm Announces 1-for-15 Reverse Stock SplitFebruary 24, 2025 | finanznachrichten.deKaryopharm implementing 1-for-15 reverse stock splitFebruary 24, 2025 | markets.businessinsider.comKaryopharm Announces 1-for-15 Reverse Stock SplitFebruary 24, 2025 | prnewswire.comLeerink Partnrs Has Pessimistic View of KPTI FY2025 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2025 earnings per share estimates for shares of Karyopharm Therapeutics in a research note issued to investors on Wednesday, February 19th. Leerink Partnrs analyst J. Chang now expFebruary 24, 2025 | marketbeat.comResearch Analysts Offer Predictions for KPTI Q1 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at HC Wainwright lifted their Q1 2025 earnings per share estimates for shares of Karyopharm Therapeutics in a research note issued on Thursday, February 20th. HC Wainwright analyst E. White now forecasts that the company wiFebruary 24, 2025 | marketbeat.comAnalysts Set Expectations for KPTI Q1 EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Leerink Partnrs issued their Q1 2025 earnings estimates for Karyopharm Therapeutics in a research report issued on Wednesday, February 19th. Leerink Partnrs analyst J. Chang forecasts that the company will post earnings of ($0.26) per shaFebruary 22, 2025 | marketbeat.comRoyal Bank of Canada Reaffirms "Outperform" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)Royal Bank of Canada restated an "outperform" rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Thursday.February 21, 2025 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for Karyopharm Therapeutics (NASDAQ:KPTI)HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday.February 21, 2025 | marketbeat.comBarclays Sticks to Its Buy Rating for Karyopharm Therapeutics (KPTI)February 20, 2025 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPSKaryopharm Therapeutics (NASDAQ:KPTI - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($0.26) by $0.02.February 20, 2025 | marketbeat.comKaryopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for FundingFebruary 20, 2025 | tipranks.comKaryopharm Therapeutics (KPTI) Q4 2024 Earnings Call TranscriptFebruary 19, 2025 | finance.yahoo.comKaryopharm Therapeutics Inc. 2024 Q4 - Results - Earnings Call PresentationFebruary 19, 2025 | seekingalpha.comKaryopharm sees FY25 revenue $140M-$155M, consensus $165.5MFebruary 19, 2025 | markets.businessinsider.comKaryopharm reports Q4 EPS (24c), consensus (27c)February 19, 2025 | markets.businessinsider.comKaryopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company ProgressFebruary 19, 2025 | prnewswire.comKaryopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Crosses Below 200-Day Moving Average - Here's WhyFebruary 18, 2025 | marketbeat.comAntengene Announces XPOVIO® Approved for Public Health Insurance Coverage in Taiwan Market, Benefiting More Patients with R/R MM in the RegionFebruary 13, 2025 | prnewswire.comKaryopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025February 12, 2025 | prnewswire.comRBC Capital Sticks to Their Buy Rating for Karyopharm Therapeutics (KPTI)February 10, 2025 | markets.businessinsider.comKaryopharm Therapeutics' (KPTI) Outperform Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reissued an "outperform" rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a research report on Monday.February 10, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average - Time to Sell?Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below Two Hundred Day Moving Average - What's Next?February 5, 2025 | marketbeat.comKaryopharm awards stock options to top executivesFebruary 2, 2025 | msn.comKaryopharm increases authorized shares, approves reverse splitJanuary 31, 2025 | msn.comKaryopharm Therapeutics' SWOT analysis: biotech stock faces pivotal yearJanuary 27, 2025 | msn.comPiper Sandler Issues a Buy Rating on Karyopharm Therapeutics (KPTI)January 27, 2025 | markets.businessinsider.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200 Day Moving Average - What's Next?Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedJanuary 25, 2025 | marketbeat.comBarclays PLC Has $79,000 Holdings in Karyopharm Therapeutics Inc. (NASDAQ:KPTI)Barclays PLC trimmed its position in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 89.0% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,767 shares of the company's stock afJanuary 25, 2025 | marketbeat.comHC Wainwright Issues Pessimistic Outlook for KPTI EarningsKaryopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) - Stock analysts at HC Wainwright cut their FY2024 earnings estimates for Karyopharm Therapeutics in a research note issued to investors on Wednesday, January 15th. HC Wainwright analyst E. White now anticipates that the company will post eJanuary 17, 2025 | marketbeat.comEdward White Recommends ‘Buy’ on Karyopharm Therapeutics Amid Promising Outlook and Strategic DevelopmentsJanuary 15, 2025 | markets.businessinsider.comKaryopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Karyopharm Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.com Remove Ads Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Media Mentions By Week KPTI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KPTI News Sentiment▼0.340.61▲Average Medical News Sentiment KPTI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KPTI Articles This Week▼23▲KPTI Articles Average Week Remove Ads Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Greenwich LifeSciences News Today Journey Medical News Today Seres Therapeutics News Today Alector News Today Enanta Pharmaceuticals News Today Eupraxia Pharmaceuticals News Today Lexeo Therapeutics News Today Zentalis Pharmaceuticals News Today C4 Therapeutics News Today Instil Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KPTI) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPTI Stock Free KPTI Stock Alerts